ABSTRACT Ras guanyl nucleotide-releasing protein 2 (RASGRP2), one of the Ras guanine exchange factors, is implicated as a critical regulator of inside-out integrin activation in human lymphocytes, neutrophils and platelets. However, the activities of this protein in endothelial cells remain unclear. In the current study, we identify a physiological function in blood vessel formation for XRASGRP2, which is the Xenopus ortholog of mammalian RASGRP2. XRASGRP2 overexpression induced ectopic vascular formation, and XRASGRP2-knockdown embryos showed delayed vascular development. We also investigated the upstream signaling of XRASGRP2 in endothelium formation. XRASGRP2 expression was up-regulated in the presence of VEGF-A and down-regulated following VEGF-A depletion. XRASGRP2 knockdown abolished the ectopic induction of endothelial cells by VEGF-A in the posterior ventral blood island. These results suggest that XRASGRP2 is essential for vascular formation during Xenopus development.
Introduction
Vascular and hematopoietic cells are thought to arise from a common progenitor, the hemangioblast. In Xenopus, primitive red blood cells are produced exclusively in the ventral blood island (VBI), which is functionally equivalent to the extra-embryonic yolk sac blood island in mammals. The embryonic endothelial cells arise synchronously with the primitive red blood cells in the VBI. The close spatial and temporal relationships between the blood cells and endothelial cells support the hypothesis that they have a bipotential precursor, the hemangioblast (Sabin, 1920; Murray, 1932) . However, the developmental mechanism underlying the differentiation of endothelial and primitive blood cells from the hemangioblast remains unclear.
Vascular endothelial growth factors (VEGFs) are key regulators in vasculogenesis and angiogenesis (Ferrara et al., 2003) . In particular, VEGF-A is involved in the regulation of processes required for angiogenesis, i.e., endothelial cell activation, proliferation, migration, and tubule formation (Ferrara et al., 2003) . In Xenopus, the VEGF-A gene is alternatively spliced to produce the VEGF122, VEGF170, and VEGF190 isoforms, which are equivalent to murine VEGF120, VEGF164, and VEGF188, respectively (Cleaver et al., 1997) . Ectopic expression of VEGF122 changes the architecture of the developing vascular network (Cleaver et al., 1997) . Over-expression of VEGF170 induces the inhibition of expression of the hematopoietic genes α-globin and GATA-1 in the posterior blood island, as well as the excessive production of endothelial cells (Koibuchi et al., 2006) .
Signaling through Ras is one of the intracellular pathways downstream of VEGF stimulation (Doanes et al., 1999; Hood et al., 2003; Meadows et al., 2001) . Genetic ablation of either SOS, which encodes a Ras guanine nucleotide exchange factor, or NF1, which encodes a Ras GTPase-activating protein, results in cardiovascular defects (Brannan et al., 1994; Henkemeyer et al., 1995; Wang et al., 1997) . K-ras-deficient mice die having multiple defects, including defects of the hematopoietic and cardiovascular systems (Johnson et al., 1997; Koera et al., 1997) . Targeted deletion of NF1 in endothelial cells leads to multiple cardiovascular defects (Gitler et al., 2003) . The small GTPase Rap1b is required for normal angiogenesis and plays a role in the regulation of pro-angiogenic signaling in endothelial cells (Chrzanowska-Wodnicka et al., 2007) .
RasGRP2/CalDAG-GEFI is a member of the CalDAG-GEF/ RasGRP family of intracellular signaling molecules involved in the activation of the Ras superfamily (Kawasaki et al., 1998; Springett et al., 2004) . RasGRP2 contains binding sites for Ca 2+ and DAG, and a GEF domain that predominantly activates Rap1 (Kawasaki et al., 1998) . Recently, RasGRP2 was identified as a critical regulator of inside-out integrin activation in human T lymphocytes, neutrophils, and platelets (Pasvolsky et al., 2007) . RasGRP3 is expressed in embryonic blood vessels and newly formed vessels during pregnancy and tumorigenesis in adults. RasGRP3 expression is upregulated by VEGF stimulation of endothelial cells (Roberts et al., 2004) . In Xenopus, XRASGRP2 is expressed in the vascular region of the embryo (Nagamine et al., 2008) .
In the present study, we reveal the role of XRASGRP2 in Xenopus vascular development by showing that: 1) over-expression of XRASGRP2 induces ectopic endothelial cell differentiation; 2) XRASGRP2-knockdown embryos show reduction or delay of endothelial cell differentiation; and 3) XRASGRP2 expression is induced by VEGF-A signaling. Our findings indicate that XRASGRP2 is essential for vascular development in downstream of VEGF-A signaling in Xenopus embryos.
Results

XRASGRP2 expression is restricted in Xenopus developing vessels
Previously, it was shown that Xenopus laevis RASGRP2 (XRASGRP2) is expressed in the vascular regions of stage 35 embryos (Nagamine et al., 2008) . We examined in detail XRASGRP2 expression during vascular development. XRASGRP2 mRNA was found to be expressed in vascular regions, such as the anterior cardinal vein (ACV), aortic arch (AA), intersomitic vein (ISV), posterior cardinal vein (PCV), and vascular vitelline network (VVN) at stage 30 (Fig. 1A) . The expression levels of XRASGRP2 mRNA in the ACV, AA, and ISV were reduced at stage 35 (Fig. 1B) . At stage 40, XRASGRP2 expression was restricted to the PCV and VVN (Fig.  1C) . In contrast, the expression of Ami, which is a vascular-specific gene, was detected in the ACV, AA, and VVN, but not in the ISV and PCV, at stage 30 (Fig. 1D) . At stage 35, expression of Ami was detected in the ACV, AA, ISV, PCV, and VVN (Fig. 1E) . These results 
Over-expression of XRASGRP2 induces ectopic expression of Xmsr
We examined the function of XRASGRP2 in vascular development. XRASGRP2 mRNA and β-galactosidase (β-gal) mRNA were injected into dorsal-vegetal (DV) or ventral-vegetal (VV) blastomeres at the 8-cell stage. DV and VV blastomeres contain components of future VBI cells. The injected embryos showed the edema phenotype at the tail-bud stage, and this phenotype was more severe at stage 43 (75%, n=56), as compared to uninjected control embryos (6%, n=72) (Fig. 2 A,B) . It was assumed that over-expression of XRASGRP2 influences cardiovascular development. Whole-mount in situ hybridization revealed that the expression of globin T3 was suppressed in the VBI (Fig. 2D) , and that ectopic expression of Xmsr was induced (Fig. 2F) in the XRASGRP2-injected embryos (Fig. 2 C,E) . Xmsr, which is the (Devic et al., 1996; . These results indicate that the over-expression of XRASGRP2 alters vascular and hematopoietic cell fates, leading to the replacement of blood cells with endothelial cells.
Knockdown of XRASGRP2 disrupts vascular development
The antisense XRASGRP2-MOs (aS-MO and bS-MO) were designed to block splicing at the first exon/intron boundaries (Fig. 3A , see Materials and Methods). These MOs inhibit the normal splicing of XRASGRP2 pre-mRNA, resulting in the production of a truncated protein that lacks the functional domain. RT-PCR analysis revealed that the level of the normally spliced transcript (312-bp band) was reduced in aS-MOor bS-MO-injected embryos (Fig. 3B, lanes aS and bS) . Normally spliced transcripts were not detected in the aS-MO and heads) of the S-MO-injected sides. The suppression of Ami expression at the S-MO-injected side was gradually mitigated as the embryos developed (Fig. 3G) . The S-MO-injected embryo showed no significant changes in globin T3 expression under the conditions used in the present study (Fig. 3H ).
VEGF-A signaling regulates the expression of XRASGRP2 and acts through XRASGRP2 in vascular development VEGF-A is a key factor in vasculogenesis and induces endothelial gene expression. A functional analysis of VEGF in
Xenopus embryos was performed by injecting VEGF-A mRNA or VEGF-A-MO into dorsal-vegetal blastomeres or ventralvegetal blastomeres at the 8-cell stage (Koibuchi et al., 2006) . We then examined the impact of signaling upstream of XRASGRP2 on vascular development. VEGF-A mRNA or VEGF-A-MO was injected into dorsal-vegetal blastomeres or ventralvegetal blastomeres, together with β-gal mRNA, at the 8-cell bS-MO co-injected embryos (Fig. 3B, lane S) . These results indicate that aS-MO and bS-MO effectively inhibit XRASGRP2 gene splicing and production of the intact protein. To investigate the role of XRASGRP2 in normal vascular development, a mixture of XRASGRP2-MOs (S-MO) was injected into one side of the 2-cell-stage embryos. The embryos were fixed at stage 31, to analyze the expression levels of the vascular-specific marker genes Xflk-1, Xmsr, Xtie2, and Ami (Fig. 3 C-F) . The expression levels of Xflk-1 and Xmsr were reduced in the PCV and ISV, respectively (Fig. 3 C,D, arrows) , and the expression levels of Xtie2 and Ami were suppressed in the PCV and VVN (Fig. 3 E stage. The number of XRASGRP2-positive cells increased in the area that was injected with VEGF-A mRNA (Fig. 4 B,C,G) . In contrast, XRASGRP2 expression was reduced in the VVN at stage 32 in the VEGF-A-MO-injected embryos (Fig. 4 D,E,I , arrow). These results indicate that VEGF-A induces XRASGRP2 expression, and that VEGF-A is required for XRASGRP2 expression. In the VEGF-A mRNA-injected embryos, ectopic induction of endothelial cells that expressed Xmsr and inhibition of globin T3 expression were observed (Fig. 5 B,E) . When VEGF-A mRNA and the XRASGRP2 S-MO were co-injected, the ectopic expression of Xmsr was decreased (Fig. 5 E,F) and the expression of globin T3 was partially rescued (Fig. 5 B,C) . These results suggest that VEGF signaling acts through XRASGRP2 in vascular development.
Discussion
In humans, RasGRP2 has been identified as a critical regulator of inside-out integrin activation in T lymphocytes, neutrophils, and platelets (Pasvolsky et al., 2007) . In adult rodents, RasGRP2 is expressed in platelets, megakaryocytes, and neutrophils within the hematopoietic system, as well as in neurons, especially in the striatum of the basal ganglia (Crittenden et al., 2004; Kawasaki et al., 1998) . The expression of XRASGRP2 in the developing vascular system was reported in Xenopus (Nagamine et al., 2008) . This XRASGRP2 expression coincided with that of Xflk-1 and Xmsr, and occurred earlier than the expression of Ami. XRASGRP2 expression was found to be transient in the developing vascular regions (Fig. 1) (Cleaver et al., 1997; Devic et al., 1996; . These results indicate that XRASGRP2 plays a role in the early phase of vasculogenesis.
In the present study, the edema phenotype was observed for both the up-regulation and down-regulation of XRASGRP2. It was reported that VEGF-A overexpression induced edema (Koibuchi et al., 2006) . VEGF-A overexpression led to the formation of ectopic blood vessels and reduced blood circulation. In contrast, c-myc-knockdown embryos showed decreased vessel formation and had the edema phenotype (Rodrigues et al., 2008) . These results indicate that an appropriate level and precise timing of blood vessel formation are required for normal development.
The XRASGRP2-knockdown embryos showed the edema phenotype, which may be due to circulation problems (data not shown) and inhibition of endothelial gene expression (Fig. 3 C-F) . This outcome indicates that XRASGRP2 is necessary for endothelial differentiation. However, the delayed vessel formation observed on the XRASGRP2-depleted side was gradually mitigated (Fig. 3G) . This indicates that some other molecules partly compensate for the lack of XRASGRP2 function. It has been reported that RasGRP3 is expressed in endothelial cells in the developing mouse embryo, although a loss-of-function mutation in RasGRP3 did not affect mouse embryo viability (Roberts et al., 2004) . Genetic ablation of Sos in the mouse resulted in death at mid-gestation, with evidence of cardiovascular and yolk sac defects (Qian et al., 2000; Wang et al., 1997) . These orthologs are candidates for the factors that compensate for the loss of XRASGRP2 function in Xenopus vasculogenesis.
VEGF plays a central role in vascular development (Ferrara et al., 2003) . VEGF-A signaling is necessary and sufficient for promoting early endothelial differentiation in Xenopus. Overexpression of VEGF-A caused ectopic expression of XRASGRP2 (Fig. 4 B,C,G) , similar to that of Xmsr and Xtie2 (Fig. 5 , Koibuchi et al., 2006) . In addition, XRASGRP2 expression was suppressed in VEGF-A-disrupted embryos (Fig. 4) . The over-expression of XRASGRP2 resulted in ectopic expression of Xmsr, similar to the over-expression of VEGF-A (Figs. 2 and 4) . These results indicate that VEGF-A is the endogenous upstream factor of XRASGRP2 in Xenopus endothelial cell differentiation.
The XRASGRP2 S-MO inhibited the ectopic expression of the genes induced by VEGF-A over-expression (Fig. 5) , which suggests that XRASGRP2 is necessary for VEGF-A to induce endothelial cell differentiation. Therefore, the expression of XRASGRP2 is regulated by VEGF-A signaling, and the induced XRASGRP2 facilitates or maintains VEGF-A signaling for endothelial cell differentiation. We propose a model for the function of RASGRP2 in vasculogenesis (Fig. 6) . In hemangioblasts, the VEGF signal induces XRASGRP2 expression. XRASGRP2 directs the cell fate towards the endothelial lineage. Since RasGRP is an activator of members of the small GTPase family, such as Ras and Rap1, these molecules are candidate targets of RASGRP2 in endothelial differentiation. Further studies are required to elucidate the role of XRASGRP2 in VEGF signal transduction and to identify the target molecule of XRASGRP2 in vasculogenesis.
Materials and Methods
Plasmid constructs
The following constructs were generated for in vitro RNA synthesis: pCS2P-XRASGRP2, which contains the ORF of Xenopus RASGRP2; and pCS2-VEGF-A, which contains the ORF of Xenopus VEGF-Ab (isoform 4, VEGF168, DQ481238). The plasmids were generated by PCR amplification using the Phusion High Fidelity PCR Kit (Finnzymes, Fin- land) followed by subcloning into the pCS2+ vector (Turner and Weintraub, 1994) .
Morpholino oligonucleotide design and validation
We obtained the sequences of the XRASGRP2a and XRASGRP2b genes of X. laevis (corresponding to the pseudo-tetraploid genome) from the database. Through prediction using the Xenopus tropicalis genomic sequence, the following common primers for exons 1 and 3 of XRASGRP2a and XRASGRP2b were generated: forward, 5'-CTGATCTTGATAAGGGTCTCACCA-3'; reverse, 5'-CTGTTTCCTTTGTTCTCCAG-3'. DNA fragments that encompassed intron 1, exon 2, and intron 2 were amplified from X. laevis genomic DNA, and then sequenced. The following XRASGRP2 antisense morpholino oligonucleotides (MOs) were designed based on the boundary between exon 1 and intron 1: XRASGRP2a splice inhibition MO (aS-MO), 5'-CAGAACTTTAGAAGCCTTACCAAAG-3'; and XRASGRP2b splice inhibition MO (bS-MO), 5'-AGAAATTTAGAACCCATACCGAAGC-3'. The MOs were obtained from Gene Tools LLC. The effects of the MOs were confirmed by RT-PCR using the above-mentioned XRASGRP2 common primers. VEGF-A-MO has been described previously (Kalin et al., 2007) .
Embryos and microinjection
Embryonic stage was determined according to the scheme of Nieuwkoop and Faber (Nieuwkoop and Faber, 1994) . The jelly coat was removed with Steinberg's solution that contained 4% cysteine hydrochloride (pH 8.0). Microinjection was carried out according to the previously described method (Chan et al., 2000) . The β-galactosidase (β-gal) mRNA was used as a lineage tracer. The β-gal -injected embryos were processed for RedGal staining (Research Organics), to reveal β-galactosidase activity.
Whole-mount in situ hybridization
Whole-mount in situ hybridization was performed as previously described (Harland, 1991; Abe et al., 2004) . Digoxigenin-labeled probes were synthesized from linearized plasmids that encode Xflk-1 (Cleaver et al., 1997) , Xmsr (Devic et al., 1996) , Xtie2 (Iraha et al., 2002) , Ami , XRASGRP2, and globin T3 (Banville and Williams, 1985) .
